Humanigen Inc. (NASDAQ:HGEN) has a beta value of -0.99 and has seen 2.38 million shares traded in the last trading session. The company, currently valued at $16.95M, closed the last trade at $0.15 per share which meant -2.47% during that session. The HGEN stock price is -2640.0% off its 52-week high price of $4.11 and 40.0% above the 52-week low of $0.09. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.63 million shares traded. The 3-month trading volume is 2.73 million shares.
The consensus among analysts is that Humanigen Inc. (HGEN) is an Underweight stock at the moment, with a recommendation rating of 3.20. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 3 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.06.
Humanigen Inc. (NASDAQ:HGEN) trade information
Sporting -2.47% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 01/23/23 when the HGEN stock price touched $0.15 or saw a rise of 15.25%. Year-to-date, Humanigen Inc. shares have moved 25.00%, while the 5-day performance has seen it change -15.25%. Over the past 30 days, the shares of Humanigen Inc. (NASDAQ:HGEN) have changed 36.36%. Short interest in the company has seen 5.38 million shares shorted with days to cover at 2.54.
Wall Street analysts have a consensus price target for the stock at $3.22, which means that the shares’ value could jump 95.34% from current levels. The projected low price target is $0.15 while the price target rests at a high of $9.00. In that case, then, we find that the current price level is -5900.0% off the targeted high while a plunge would see the stock lose 0.0% from current levels.
Humanigen Inc. (HGEN) estimates and forecasts
Figures show that Humanigen Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -65.34% over the past 6 months, with this year growth rate of 69.80%, compared to 4.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are 88.70% and 71.90% for the next quarter. Revenue growth from the last financial year stood is estimated to be -35.20%.
1 analysts offering their estimates for the company have set an average revenue estimate of $100k for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 21.90% over the past 5 years. Earnings growth for 2023 is a modest -66.90% while over the next 5 years, the company’s earnings are expected to increase by 12.50%.
Humanigen Inc. is expected to release its next earnings report between February 27 and March 03 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Humanigen Inc. (NASDAQ:HGEN)’s Major holders
Insiders own 11.96% of the company shares, while shares held by institutions stand at 6.11% with a share float percentage of 6.93%. Investors are also buoyed by the number of investors in a company, with Humanigen Inc. having a total of 69 institutions that hold shares in the company. The top two institutional holders are Gsa Capital Partners Llp with over 1.03 million shares worth more than $0.15 million. As of Sep 29, 2022, Gsa Capital Partners Llp held 0.49% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 0.95 million shares as of Sep 29, 2022. The firm’s total holdings are worth over $0.14 million and represent 0.45% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund. As of Sep 29, 2022, the former fund manager holds about 0.32% shares in the company for having 0.68 million shares of worth $0.1 million while later fund manager owns 0.27 million shares of worth $40977.0 as of Nov 29, 2022, which makes it owner of about 0.13% of company’s outstanding stock.